Enliven Therapeutics Inc Financials
This page shows Enliven Therapeutics Inc (ELVN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Enliven Therapeutics Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Enliven Therapeutics Inc generates $0.82 in operating cash flow (-$73.2M OCF vs -$89.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Enliven Therapeutics Inc's EBITDA was -$104.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 25.3% from the prior year.
Enliven Therapeutics Inc generated -$73.2M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 19.2% from the prior year.
Enliven Therapeutics Inc reported -$89.0M in net income in fiscal year 2024. This represents a decrease of 24.4% from the prior year.
Enliven Therapeutics Inc earned $-1.89 per diluted share (EPS) in fiscal year 2024. This represents an increase of 6.0% from the prior year.
Enliven Therapeutics Inc held $124.1M in cash against $0 in long-term debt as of fiscal year 2024.
Enliven Therapeutics Inc had 49M shares outstanding in fiscal year 2024. This represents an increase of 18.5% from the prior year.
Enliven Therapeutics Inc invested $80.8M in research and development in fiscal year 2024. This represents an increase of 25.1% from the prior year.
Enliven Therapeutics Inc invested $44K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 70.5% from the prior year.
ELVN Income Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $18.2M-14.3% | $21.3M | N/A | $19.6M | N/A | $7.8M | N/A | $10.4M |
| SG&A Expenses | $6.9M+18.3% | $5.8M | N/A | $4.6M | N/A | $3.1M | N/A | $3.3M |
| Operating Income | -$25.1M+7.3% | -$27.1M | N/A | -$24.2M | N/A | -$10.9M | N/A | -$13.7M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $0 | $0 | N/A | $0 | N/A | N/A | N/A | N/A |
| Net Income | -$20.1M+13.0% | -$23.2M | N/A | -$20.8M | N/A | -$10.6M | N/A | -$13.6M |
| EPS (Diluted) | $-0.32+33.3% | $-0.48 | N/A | $-0.51 | N/A | $-3.27 | N/A | $-0.74 |
ELVN Balance Sheet
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $490.9M+50.7% | $325.8M+19.8% | $271.9M-0.8% | $274.0M+229.0% | $83.3M+40.9% | $59.1M-47.8% | $113.3M+5.9% | $107.0M |
| Current Assets | $482.7M+51.7% | $318.1M+19.5% | $266.2M-0.9% | $268.6M+245.5% | $77.8M+31.6% | $59.1M-46.6% | $110.7M+4.4% | $106.0M |
| Cash & Equivalents | $101.7M-18.0% | $124.1M+23.9% | $100.1M+35.6% | $73.8M-2.2% | $75.5M-12.3% | $86.2M-21.7% | $110.0M+46.1% | $75.3M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $14.8M-7.3% | $15.9M-38.7% | $26.0M+111.2% | $12.3M-92.3% | $160.1M+25.9% | $127.2M-18.6% | $156.2M+1941.0% | $7.7M |
| Current Liabilities | $14.7M-7.9% | $15.9M-38.5% | $25.9M+114.4% | $12.1M+24.3% | $9.7M+434.4% | $1.8M-68.4% | $5.8M-20.0% | $7.2M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $476.1M+53.7% | $309.8M+26.0% | $245.9M-6.1% | $261.7M+440.7% | -$76.8M-12.8% | -$68.1M-58.8% | -$42.9M-143.2% | $99.4M |
| Retained Earnings | -$317.5M-30.4% | -$243.5M-57.6% | -$154.4M-14.3% | -$135.1M-63.0% | -$82.9M+53.5% | -$178.2M-294.2% | -$45.2M+66.1% | -$133.2M |
ELVN Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$13.3M+22.8% | -$17.2M-37.8% | -$12.5M+21.5% | -$15.9M-95.1% | -$8.1M-26.3% | -$6.4M-142.5% | $15.2M+239.0% | -$10.9M |
| Capital Expenditures | -$1K | $0-100.0% | $14K-12.5% | $16K-84.2% | $101K+621.4% | $14K-92.2% | $179K | $0 |
| Free Cash Flow | -$13.3M+22.8% | -$17.2M-37.7% | -$12.5M+21.5% | -$15.9M-92.9% | -$8.2M-27.6% | -$6.5M-143.2% | $15.0M+237.4% | -$10.9M |
| Investing Cash Flow | -$4.1M-658.2% | $727K-98.1% | $38.7M+208.8% | -$35.5M-35097.0% | -$101K-621.4% | -$14K+99.9% | -$13.1M-47.8% | -$8.8M |
| Financing Cash Flow | -$368K-100.9% | $40.0M+44313.3% | $90K+121.2% | -$425K+82.1% | -$2.4M-1549.4% | $164K+100.3% | -$50.1M-206.7% | $47.0M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ELVN Financial Ratios
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -4.1%+3.5pp | -7.6% | N/A | -7.6% | N/A | -17.9% | N/A | -12.8% |
| Current Ratio | 32.95+13.0 | 19.99+9.7 | 10.28-12.0 | 22.24+14.2 | 8.00-24.5 | 32.51+13.3 | 19.24+4.5 | 14.75 |
| Debt-to-Equity | 0.03-0.0 | 0.05-0.1 | 0.11+0.1 | 0.05+2.1 | -2.08-0.2 | -1.87+1.8 | -3.64-3.7 | 0.08 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Enliven Therapeutics Inc profitable?
No, Enliven Therapeutics Inc (ELVN) reported a net income of -$89.0M in fiscal year 2024.
What is Enliven Therapeutics Inc's earnings per share (EPS)?
Enliven Therapeutics Inc (ELVN) reported diluted earnings per share of $-1.89 for fiscal year 2024. This represents a 6.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Enliven Therapeutics Inc's EBITDA?
Enliven Therapeutics Inc (ELVN) had EBITDA of -$104.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Enliven Therapeutics Inc's free cash flow?
Enliven Therapeutics Inc (ELVN) generated -$73.2M in free cash flow during fiscal year 2024. This represents a -19.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Enliven Therapeutics Inc's operating cash flow?
Enliven Therapeutics Inc (ELVN) generated -$73.2M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Enliven Therapeutics Inc's total assets?
Enliven Therapeutics Inc (ELVN) had $325.8M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Enliven Therapeutics Inc's capital expenditures?
Enliven Therapeutics Inc (ELVN) invested $44K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Enliven Therapeutics Inc spend on research and development?
Enliven Therapeutics Inc (ELVN) invested $80.8M in research and development during fiscal year 2024.
How many shares does Enliven Therapeutics Inc have outstanding?
Enliven Therapeutics Inc (ELVN) had 49M shares outstanding as of fiscal year 2024.
What is Enliven Therapeutics Inc's current ratio?
Enliven Therapeutics Inc (ELVN) had a current ratio of 19.99 as of fiscal year 2024, which is generally considered healthy.
What is Enliven Therapeutics Inc's debt-to-equity ratio?
Enliven Therapeutics Inc (ELVN) had a debt-to-equity ratio of 0.05 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Enliven Therapeutics Inc's return on assets (ROA)?
Enliven Therapeutics Inc (ELVN) had a return on assets of -27.3% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Enliven Therapeutics Inc's cash runway?
Based on fiscal year 2024 data, Enliven Therapeutics Inc (ELVN) had $124.1M in cash against an annual operating cash burn of $73.2M. This gives an estimated cash runway of approximately 20 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Enliven Therapeutics Inc's Piotroski F-Score?
Enliven Therapeutics Inc (ELVN) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Enliven Therapeutics Inc's earnings high quality?
Enliven Therapeutics Inc (ELVN) has an earnings quality ratio of 0.82x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.